{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:52:41Z","timestamp":1795027961228,"version":"4.10.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare, chronic, debilitating, unpredictable, and potentially life-threatening neuromuscular disease. There is a lack of real-world data on disease management that could be used to further understand and address unmet patient needs and burden. We aimed to provide comprehensive real-world insights in the management of MG in five European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected using the Adelphi Real World Disease Specific Programme\u2122 in MG, a point-in-time survey of physicians and their patients with MG in France, Germany, Italy, Spain, and the United Kingdom (UK). Physician- and patient-reported clinical data were collected, including demographics, comorbidities, symptoms, disease history, treatments, healthcare resource utilization (HCRU), and quality of life outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 144 physicians completed 778 patient record forms from March to July 2020 in the UK, and from June to September 2020 in France, Germany, Italy and Spain. Mean patient age at symptom onset was 47.7\u00a0years, with a mean time from symptom onset to diagnosis of 332.4\u00a0days (10.97\u00a0months). At diagnosis, 65.3% of patients were classified as Myasthenia Gravis Foundation of America Class II or above. Mean number of symptoms reported at diagnosis per patient was five, with ocular myasthenia reported in at least 50% of patients. At time of survey completion, the mean number of symptoms reported per patient was five and ocular myasthenia and ptosis were each still present in more than 50% of patients. Acetylcholinesterase inhibitors were the most commonly prescribed chronic treatments in all countries. Of 657 patients treated with chronic treatment at the time of the survey, 62% continued to experience moderate-to-severe symptoms. On average, 3.1 healthcare professionals (HCPs) were involved in patient management, 6.2 consultations were made per patient with any HCP over the last 12\u00a0months, and 178 (22.9%) patients were hospitalized in the last 12\u00a0months. Overall, HCRU and disease management were similar across all countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrated the high burden of MG despite current treatment options for patients with MG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02727-0","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T06:02:09Z","timestamp":1688018529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey"],"prefix":"10.1186","volume":"18","author":[{"given":"Milada","family":"Mahic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bozorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"DeCourcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4727-9243","authenticated-orcid":false,"given":"Anna","family":"Scowcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"issue":"8","key":"2727_CR1","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"issue":"10","key":"2727_CR2","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/pds.4962","volume":"29","author":"J Wu","year":"2020","unstructured":"Wu J, Wang C, Toh S, Pisa FE, Bauer L. Use of real-world evidence in regulatory decisions for rare diseases in the United States \u2013 current status and future directions. Pharmacoepidemiol Drug Saf. 2020;29(10):1213\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2727_CR3","unstructured":"European Commission. Rare diseases 2021 [cited 2021 October]. Available from: https:\/\/ec.europa.eu\/info\/research-and-innovation\/research-area\/health-research-and-innovation\/rare-diseases_en."},{"key":"2727_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2727_CR5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"issue":"1","key":"2727_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"key":"2727_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","volume":"11","author":"LS Borges","year":"2020","unstructured":"Borges LS, Richman DP. Muscle-specific kinase myasthenia gravis. Front Immunol. 2020;11:707.","journal-title":"Front Immunol"},{"issue":"5","key":"2727_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, et al. Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled multicenter clinical trial. JAMA Neurol. 2020;77(5):582\u201392.","journal-title":"JAMA Neurol"},{"issue":"Pt 4","key":"2727_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","volume":"135","author":"R Klooster","year":"2012","unstructured":"Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012;135(Pt 4):1081\u2013101.","journal-title":"Brain"},{"issue":"5","key":"2727_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","volume":"8","author":"MN Meriggioli","year":"2012","unstructured":"Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427\u201338.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2727_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2727_CR12","doi-asserted-by":"publisher","first-page":"e048198","DOI":"10.1136\/bmjopen-2020-048198","volume":"11","author":"S Berrih-Aknin","year":"2021","unstructured":"Berrih-Aknin S, Claeys KG, Law N, Mantegazza R, Murai H, Sacca F, et al. Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open. 2021;11(7):e048198.","journal-title":"BMJ Open"},{"issue":"3","key":"2727_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"2","key":"2727_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1102\u201325.","journal-title":"Neurol Ther"},{"issue":"11","key":"2727_CR15","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes \u2013 a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"2727_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2727_CR17","volume-title":"Self-reported population health: an international perspective based on EQ-5D","year":"2014","unstructured":"Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014."},{"issue":"6","key":"2727_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve. 2019;60(6):707\u201315.","journal-title":"Muscle Nerve"},{"issue":"4","key":"2727_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","volume":"11","author":"M Mahic","year":"2022","unstructured":"Mahic M, Bozorg AM, DeCourcy JJ, Golden KJ, Gibson GA, Taylor CF, et al. Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey. Neurol Ther. 2022;11(4):1535\u201351.","journal-title":"Neurol Ther"},{"issue":"10","key":"2727_CR20","doi-asserted-by":"publisher","first-page":"e00538","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.","journal-title":"Brain Behav"},{"key":"2727_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2377-13-132","volume":"13","author":"A Elsais","year":"2013","unstructured":"Elsais A, Wyller VB, Loge JH, Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol. 2013;13:132.","journal-title":"BMC Neurol"},{"key":"2727_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","volume":"8","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, Pohlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2727_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166\u201373.","journal-title":"Muscle Nerve"},{"issue":"11","key":"2727_CR24","doi-asserted-by":"publisher","first-page":"e0206754","DOI":"10.1371\/journal.pone.0206754","volume":"13","author":"A Jeong","year":"2018","unstructured":"Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, et al. Factors associated with quality of life of people with Myasthenia Gravis. PLoS One. 2018;13(11):e0206754.","journal-title":"PLoS One"},{"key":"2727_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13:115.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2727_CR26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","volume":"33","author":"IZ Basta","year":"2012","unstructured":"Basta IZ, Pekmezovic TD, Peric SZ, Kisic-Tepavcevic DB, Rakocevic-Stojanovic VM, Stevic ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci. 2012;33(6):1375\u201381.","journal-title":"Neurol Sci"},{"issue":"6","key":"2727_CR27","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"key":"2727_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fpsyt.2019.00481","volume":"10","author":"HT Chu","year":"2019","unstructured":"Chu HT, Tseng CC, Liang CS, Yeh TC, Hu LY, Yang AC, et al. Risk of depressive disorders following myasthenia gravis: a nationwide population-based retrospective cohort study. Front Psychiatry. 2019;10:481.","journal-title":"Front Psychiatry"},{"issue":"10312","key":"2727_CR29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700\u201312.","journal-title":"Lancet"},{"key":"2727_CR30","unstructured":"Mahic M, Zaremba P, Rudnik J, Bozorg A, Dolin P. Currently used therapies for myasthenia gravis do not provide adequate disease control for all patients: a retrospective analysis of United States claims data. American Association of Neuromuscular & Electrodiagnostic Medicine; 13\u201316 October, 2021; Virtual."},{"issue":"4","key":"2727_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"2727_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists' management guidelines. Pract Neurol. 2015;15(3):199\u2013206.","journal-title":"Pract Neurol"},{"issue":"7","key":"2727_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13696998.2019.1592180","volume":"22","author":"L Harris","year":"2019","unstructured":"Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S. Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. J Med Econ. 2019;22(7):691\u20137.","journal-title":"J Med Econ"},{"issue":"1","key":"2727_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","volume":"10","author":"H Murai","year":"2019","unstructured":"Murai H, Hasebe M, Murata T, Utsugisawa K. Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database. Clin Exp Neuroimmunol. 2019;10(1):61\u20138.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"14","key":"2727_CR35","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurology. 2021;97(14):e1382\u201391.","journal-title":"Neurology"},{"key":"2727_CR36","doi-asserted-by":"publisher","first-page":"175628642211503","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disord. 2023;16:17562864221150327.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2727_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","volume":"67","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: a United States health claims analysis. Muscle Nerve. 2023;67(4):297\u2013305.","journal-title":"Muscle Nerve"},{"issue":"5","key":"2727_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/0028-3886.144438","volume":"62","author":"SV Khadilkar","year":"2014","unstructured":"Khadilkar SV, Chaudhari CR, Patil TR, Desai ND, Jagiasi KA, Bhutada AG. Once myasthenic, always myasthenic? observations on the behavior and prognosis of myasthenia gravis in a cohort of 100 patients. Neurol India. 2014;62(5):492\u20137.","journal-title":"Neurol India"},{"issue":"1","key":"2727_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1(1):16\u201322.","journal-title":"Neurohospitalist"},{"key":"2727_CR40","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"2727_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","volume":"15","author":"H Xin","year":"2019","unstructured":"Xin H, Harris LA, Aban IB, Cutter G. Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol. 2019;15(3):376\u201385.","journal-title":"J Clin Neurol"},{"key":"2727_CR42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"key":"2727_CR43","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.","journal-title":"BMJ"},{"key":"2727_CR44","doi-asserted-by":"publisher","first-page":"e8497","DOI":"10.1136\/bmj.e8497","volume":"345","author":"J Spillane","year":"2012","unstructured":"Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ. 2012;345:e8497.","journal-title":"BMJ"},{"key":"2727_CR45","unstructured":"Mahic M, Zaremba Z, Rudnik J, Bozorg A, Dolin P. Management of myasthenia gravis generates a high healthcare burden: a retrospective analysis of United States claims data. American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting; October 13\u201316, 2021; Virtual."},{"key":"2727_CR46","unstructured":"Ettelt S, Nolte E, Mays N, Thomson S, Mckee M, editors. Health care outside hospital: accessing generalist and specialist care in eight countries. Policy Brief. 2006."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02727-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T07:11:12Z","timestamp":1688022672000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2727"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02727-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research obtained ethics approval from the Western Institutional Review Board, sponsor protocol number: AG8768. The Adelphi Disease Specific Programme\u2122 is Health Insurance Portability and Accountability Act compliant, and all data were aggregated and de-identified. Using a check box, patients and physicians provided informed consent to take part in the Adelphi Myasthenia Gravis Disease Specific Programme\u2122 market research survey, on which this secondary data analysis is based. Data were collected in such a way that patients and physicians could not be identified directly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Milada Mahic is a former employee of UCB Pharma and is now employed by Vertex Pharmaceuticals. Ali Bozorg is a former employee of UCB Pharma and is now employed by Otsuka Pharmaceutical Development and Commercialization, Inc. Anna Scowcroft is an employee and stockholder of UCB Pharma. Keisha Golden, Gregor Gibson and Jonathan DeCourcy are employees of Adelphi Real World. Christian Taylor is a former employee of Adelphi Real World and does not currently have an affiliation to any organization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}